SCYX
SCYNEXIS Inc
Price:  
0.83 
USD
Volume:  
61,647.00
United States | Pharmaceuticals
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

SCYX WACC - Weighted Average Cost of Capital

The WACC of SCYNEXIS Inc (SCYX) is 8.7%.

The Cost of Equity of SCYNEXIS Inc (SCYX) is 8.90%.
The Cost of Debt of SCYNEXIS Inc (SCYX) is 8.60%.

Range Selected
Cost of equity 5.70% - 12.10% 8.90%
Tax rate 3.50% - 6.00% 4.75%
Cost of debt 7.00% - 10.20% 8.60%
WACC 6.0% - 11.4% 8.7%
WACC

SCYX WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 0.4 1.29
Additional risk adjustments 0.0% 0.5%
Cost of equity 5.70% 12.10%
Tax rate 3.50% 6.00%
Debt/Equity ratio 0.39 0.39
Cost of debt 7.00% 10.20%
After-tax WACC 6.0% 11.4%
Selected WACC 8.7%

SCYX's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for SCYX:

cost_of_equity (8.90%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (0.4) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.